Insights

Cardiovascular focus Kiniksa specializes in novel therapies for cardiovascular indications with unmet need, presenting a clear market leverage for partnerships or co-development in high-value cardiac diseases.

Strong financials With quarterly revenue approaching mid-hundreds of millions and net income improvements driven by clinical investments and commercialization, there is a solid base for exploring scalable collaboration or licensing deals.

Strategic leadership Recent executive transitions, including the Chief Strategy Officer resignation, signal potential appetite for strategic partnerships or advisory engagements to accelerate pipeline monetization and corporate initiatives.

Public engagement Frequent conference participation and high-visibility campaigns around recurrent pericarditis indicate opportunities for sponsored research, patient advocacy collaborations, and payer-facing demonstrations to accelerate adoption.

Technology leverage Adoption of multiple enterprise and CRM platforms (Sage Intacct, Salesforce, SAP, SuccessFactors) suggests readiness for BD activities, data partnerships, and streamlined commercial operations to scale partnerships and market access.

Similar companies to Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Tech Stack

Kiniksa Pharmaceuticals uses 8 technology products and services including Sage Intacct, iCIMS, Drupal, and more. Explore Kiniksa Pharmaceuticals's tech stack below.

Media & News

Kiniksa Pharmaceuticals's Email Address Formats

Kiniksa Pharmaceuticals uses at least 4 email formats:
Kiniksa Pharmaceuticals Email FormatsExamplePercentage
FLast@kiniksa.comJDoe@kiniksa.com
82%
F.Last@kiniksa.comJ.Doe@kiniksa.com
11%
Last@kiniksa.comDoe@kiniksa.com
3%
LFirst@kiniksa.comDJohn@kiniksa.com
4%

Frequently Asked Questions

What is Kiniksa Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Kiniksa Pharmaceuticals is a publicly traded company; the company's stock symbol is KNSA.

What is Kiniksa Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Kiniksa Pharmaceuticals's official website is kiniksa.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Kiniksa Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of October 2026, Kiniksa Pharmaceuticals's annual revenue is estimated to be $500M - $1B.

What is Kiniksa Pharmaceuticals's SIC code and NAICS code?

Minus sign iconPlus sign icon
Kiniksa Pharmaceuticals's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Kiniksa Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of October 2026, Kiniksa Pharmaceuticals has approximately 412 employees across 6 continents, including North America, Europe and Africa. Key team members include Chief Operating Officer, Executive Vice President: R. M., Vp, General Manager, Kiniksa International: D. P. and Vp, Supply Chain: R. H. Explore Kiniksa Pharmaceuticals's employee directory with LeadIQ.

What industry does Kiniksa Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Kiniksa Pharmaceuticals operates in the Biotechnology Research industry.

What technology does Kiniksa Pharmaceuticals use?

Minus sign iconPlus sign icon
Kiniksa Pharmaceuticals's tech stack includes Sage Intacct, iCIMS, Drupal, Salesforce, SAP, Microsoft Intune, SuccessFactors and WP Engine.

What is Kiniksa Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Kiniksa Pharmaceuticals's email format typically follows the pattern of FLast@kiniksa.com. Find more Kiniksa Pharmaceuticals email formats with LeadIQ.

How much funding has Kiniksa Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of October 2026, Kiniksa Pharmaceuticals has raised $400M in funding. The last funding round occurred on May 13, 2020 for $80M.

When was Kiniksa Pharmaceuticals founded?

Minus sign iconPlus sign icon
Kiniksa Pharmaceuticals was founded in 2015.
Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

Biotechnology ResearchMassachusetts, United States201-500 Employees

Kiniksa Pharmaceuticals is a mid-sized biotechnology company based in Lexington, Massachusetts, focused on discovering, acquiring, developing, and commercializing therapies for diseases with unmet medical need, with a particular emphasis on cardiovascular indications. Its portfolio rests on strong biological rationales or validated mechanisms, with the potential to differentiate its therapies in the marketplace. Across its work, the company aims to improve patients' lives by pursuing treatments for life-altering conditions.

Operating within the biotechnology research sector, Kiniksa pursues a global program aimed at building a lasting platform for developing novel therapies. A recent development is the resignation of Chief Strategy Officer Eben Tessari in May 2026.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
KNSA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
201-500

Section iconFunding & Financials

  • $400M

    Kiniksa Pharmaceuticals has raised a total of $400M of funding over 4 rounds. Their latest funding round was raised on May 13, 2020 in the amount of $80M as a Post IPO Equity.

  • $500M - $1B

    Kiniksa Pharmaceuticals's revenue is estimated to be in the range of $500M - $1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.